- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03560934
Tetrahydrocannabinol (THC) and Sleep
Effect of Tetrahydrocannabinol (THC) on Sleep in Humans
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Frequent Cannabis Use (>3x/week for the prior 3 months) or
- No Cannabis Use (Less than 10x ever)
Exclusion Criteria:
- Sleep Apnea
- Pregnancy
- Diabetes
- Cardiovascular disease
- Chronic Pain
- History of seizures
- Severe Hepatic impairment
- Conditions associated with clinically relevant cognitive impairment
- Symptoms of acute or active illness (e.g., fever and leukocytosis)
- Evidence of psychopathology on the Beck Depression Index II (BDI-II or in a structured clinical interview with a physician
- History of severe psychiatric illnesses (including such as alcoholism, drug dependency including a cannabis use disorder score ≥12 on the Cannabis Use Disorders Identification Test (CUDIT) (28) or >1 withdrawal symptom on the Marijuana Withdrawal Checklist (MWC (29)) , major depression, manic depressive illness, schizophrenic disorders, panic disorder, generalized anxiety disorder, post-traumatic stress disorder, agoraphobia, claustrophobia, paranoid personality disorder, schizoid personality disorder, schizotypal personality disorder, borderline personality disorder, and antisocial personality disorder.)
- History of having been treated with antidepressants, neuroleptic medications, or tranquilizers.
- Volunteers must be drug-free (including caffeine, nicotine, alcohol and herbal medications) for the duration of the screening and study period (with the exception of THC), with no dependence on drugs (e.g. cocaine, opioids, amphetamine, methamphetamine, PCP, benzodiazepines, barbiturates, methadone, MDMA); or alcohol dependency.
- Current Nicotine use ( or history of more than 5 'pack years' of smoking)
- Current use of prescription or over the counter medications
- History of shift work in the last 6 months
- Travel across >2 time zones during the month prior to the study
- Habitual bedtime after 1am or waketime before 5am
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Frequent Cannabis Users
Subjects categorized as frequent cannabis users (>3x/week for 3 months) will receive a single dose of 10-60mg dronabinol on the second or third night of their stay in the clinical laboratory, one hour prior to bedtime and five minutes after completion of a study snack. The other night, participants will receive a placebo. Dronabinol is an orally active, synthetic THC currently indicated for weight loss in patients with acquired immune deficiency syndrome (AIDS) or anorexia and for nausea and vomiting associated with cancer. Dronabinol is nearly absorbed (90%-95%) after a single oral dose of the capsule formulation with 10-20% of the administered dose researching the systemic circulation due to extensive first-pass hepatic metabolism and high lipid solubility. The onset of action is ~30 to 60 minutes with peak effects from 2-4-h following dose (Fig. 2) (34). The 10-60mg of dronabinol will be administered by OHSU's research pharmacy services. |
Single dose oral administration of 10-60mg dronabinol prior to night 2 or 3 sleep in the clinical laboratory.
Other Names:
|
Experimental: Non Cannabis Users
Non-cannabis users (who have not used cannabis more than 10 times in their lifetime) will undergo the same single dose dronabinol and placebo as the frequent cannabis user arm, under the identical study procedure.
|
Single dose oral administration of 10-60mg dronabinol prior to night 2 or 3 sleep in the clinical laboratory.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sleep Stages
Time Frame: Over the 3-night stay.
|
Polysomnographic recordings will be measured and scored across the three sleep periods for timing and sleep stages.
|
Over the 3-night stay.
|
Psychomotor Vigilance Change Across Four Day Inpatient Stay
Time Frame: Over the 3-night stay.
|
Psychomotor vigilance response times (in milliseconds) will be measured shortly after awakening each test morning.
|
Over the 3-night stay.
|
Mean Change in Response Accuracy for Paced Auditory Serial Addition Test Across Four Day Inpatient Stay
Time Frame: Over the 3-night stay.
|
Processing speed and working memory (response accuracy) will be measured shortly after awakening each test morning.
Scores can range from a minimum of 0 to 60 correct responses with each test.
|
Over the 3-night stay.
|
Mean Change in Response Accuracy for Word Recall Across Four Day Inpatient Stay
Time Frame: Over the 3-night stay.
|
Verbal memory will be measured shortly after awakening each test morning.
Scores can range from recalling 0 words to the complete list.
Participants are blinded as to list length.
|
Over the 3-night stay.
|
Mean changes in Intoxication Levels on the Visual Analog Scale
Time Frame: Over the 3-night stay.
|
Assessed by visual analog scale (Minimum=0, Maximum=100).
0 is "Not at all" and 100 is "Extremely".
Questions ask about feeling drug effect, high right now, and wanting more of the study drug.
|
Over the 3-night stay.
|
Blood pressure
Time Frame: Over the 3-night stay.
|
Blood pressure (BP) will be measured every 30 min during wake and every 15 minutes during sleep.
Beat-by-beat (BP) will be measured during sleep using a non-invasive device employing the volume-clamp method with hydrostatic correction (BMeye Nexfin or AD Instruments NIBP).
Additionally an automated calibrated sphygmomanometer will be used to record sporadic BP at intervals during an exercise challenge.
|
Over the 3-night stay.
|
Heart Rate
Time Frame: Over the 3-night stay.
|
For the duration of the study, 2 channels of EKG are recorded (RA-V6) and stored at a sample frequency of 256 Hz.
This software will be used for peak detection (R-wave detection and subsequent heart rate variability (HRV) analysis to estimate cardiac vagal tone).
|
Over the 3-night stay.
|
Endothelial Function
Time Frame: Over the 3-night stay.
|
Endothelial Function will be measured as Flow Mediated Dilation in the brachial artery 10 minutes after each awakening and 20 minutes before each sleep period.
|
Over the 3-night stay.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjective measures of sleepiness/alertness
Time Frame: Over the 3-night stay.
|
Subjective sleepiness and alertness will be measured regularly (~1/h) across wake periods during the study protocol using the Stanford Sleepiness Scale.
The scale measures subjective sleepiness on a 1-5 point Likert scale with 5 indicating the highest degree of sleepiness and 1 indicating the lowest degree of sleepiness.
|
Over the 3-night stay.
|
Caloric Intake
Time Frame: Over the 3-night stay.
|
Participants will use a meal logging app to log all meals and beverages consumed for caloric/nutritional content and timing for a period prior to coming into the clinical laboratory.
|
Over the 3-night stay.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Steven A Shea, PhD, Oregon Health and Science University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Marijuana Abuse
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Psychotropic Drugs
- Hallucinogens
- Cannabinoid Receptor Agonists
- Cannabinoid Receptor Modulators
- Dronabinol
Other Study ID Numbers
- IRB00018052
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep
-
University of Wisconsin, MadisonPhilips HealthcareCompletedSleep, Slow-wave Sleep, Sleep Enhancement, Sleep Optimization
-
Brain Electrophysiology Laboratory CompanyRecruiting
-
University GhentEuropean CommissionEnrolling by invitation
-
Northumbria UniversityCompletedSleep | Mood | Poor Quality Sleep | Good Sleep HabitUnited Kingdom
-
Baylor College of MedicineEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruiting
-
Brain Electrophysiology Laboratory CompanyCompletedSleep | Sleep HygieneUnited States
-
Koko Home, Inc.Stanford UniversityRecruitingSleep Disorder | Insomnia | Sleep Initiation and Maintenance Disorders | Sleep | Sleep Disturbance | Sleep HygieneUnited States
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, Wisconsin; Divine Savior...Active, not recruitingSleep | Sleep HygieneUnited States
-
Aretaieion University HospitalRecruitingSleep Disorder | Sleep Initiation and Maintenance Disorders | Sleep | Sleep Disturbance | Surgery | Anesthesia | Sleep Fragmentation | Sleep Disorders, Circadian RhythmGreece
-
Brigham and Women's HospitalCharite University, Berlin, Germany; Stanford UniversityRecruitingSleep Disorders, Intrinsic | Sleep Wake Disorders | Sleep Disorders, Circadian Rhythm | Advanced Sleep Phase Syndrome (ASPS) | Delayed Sleep Phase Syndrome | Shift-Work Sleep Disorder | Delayed Sleep Phase | Non-24 Hour Sleep-Wake Disorder | Advanced Sleep Phase Syndrome | Advanced Sleep Phase | Irregular... and other conditionsUnited States
Clinical Trials on Dronabinol
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)Completed
-
Medical University of ViennaRecruitingRetinal Blood FlowAustria
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)Completed
-
INSYS Therapeutics IncCompletedBioavailabilityUnited States
-
INSYS Therapeutics IncCompletedDrug Abuse, MedicationCanada
-
Yale UniversityCompleted
-
Wayne State UniversityCompletedPostTraumatic Stress DisorderUnited States
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA); Research Foundation for Mental Hygiene...CompletedMood | Pain ThresholdUnited States
-
Yale UniversityNational Institute on Drug Abuse (NIDA); VA Connecticut Healthcare SystemRecruitingPain, Tolerance | Oral vs Vaporized THC | Abuse LiabilityUnited States
-
Istituto di Ricerca Neuroftalmologia S.r.l.Fondazione G.B. Bietti, IRCCSCompleted